NEC OncoImmunity AS
Heinz Lubenau has an extensive work experience in the biotherapeutics and pharmaceutical industries. Heinz currently holds the position of Chief Executive Officer at NEC Bio Therapeutics since April 2023. Prior to this, they served as the Chief Drug Development Officer at NEC OncoImmunity AS starting in April 2022. Heinz also worked as a Clinical Development Director Consultant at AELIX Therapeutics from November 2021.
From 2008 to 2022, Heinz held various roles at Vaximm AG, including Chief Executive Officer, Chief Operating Officer, and General Manager and Head of Development. Before that, they worked at BioGeneriX AG - ratiopharm group as the Head of Preclinical and Clinical Development from 2003 to 2008.
Earlier in their career, Heinz gained experience at Servier, where they held several roles including Clinical Research Manager Internal Medicine, Head of Clinical Monitoring, Head of Department Clinical Research, Project Leader, Junior Project Leader, and CRA Training on the Job from 1994 to 2002.
Overall, Heinz has demonstrated progressive growth and leadership capabilities throughout their career in the pharmaceutical industry.
Heinz Lubenau obtained a Bachelor's degree in Pharmacy from Johannes Gutenberg University Mainz, which they completed between 1985 and 1990. Heinz further pursued their education at the same university and received their PhD in Pharmacy from 1991 to 1994.
This person is not in any offices
NEC OncoImmunity AS
NEC OncoImmunity AS is an artificial intelligence (AI) driven biotech company offering proprietary machine-learning software, which addresses the key gaps in the prediction of bona fide immunogenic antigens for personalized cancer immunotherapy and infectious disease vaccines. We are dedicated to developing scalable software solutions that facilitate effective patient selection for cancer immunotherapy, and identifying optimal neoantigen targets for truly personalized cancer vaccines & cell therapies in a clinically actionable time frame. Our growing international team (13 countries and counting!) consists of a diverse mix of data scientists, bioinformaticians, immunologists, cancer researchers, and software developers. NEC OncoImmunity AS is a subsidiary of the NEC Corporation, and is based in the Oslo Cancer Cluster buildings in Oslo, Norway.